JP Morgan Downgrades Seres Therapeutics to Underweight
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Tessa Romero has downgraded Seres Therapeutics (NASDAQ:MCRB) from Neutral to Underweight, indicating a less favorable outlook for the company's stock.

October 24, 2024 | 11:08 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
JP Morgan has downgraded Seres Therapeutics from Neutral to Underweight, suggesting a less favorable view on the stock's performance.
The downgrade from a major financial institution like JP Morgan can lead to a negative perception among investors, potentially causing a short-term decline in the stock price. The change from Neutral to Underweight suggests that the analyst sees less potential for positive performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100